FDC Limited

FDC Ltd is an established player in the pharmaceutical industry and a pioneer in developing specialized formulations. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics and others. The company is a market leader in the Oral Rehydration Salt category along with ophthalmic range of solutions. In the Oral Rehydration Salt category the brand leader’s Zifi and Electral crossed Rs300 crore. Barrier and Enerzal reached Rs125 crore. The company manufactures and distributes its range of generics, formulations and active pharmaceuticals at its manufacturing plants. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include AlbuterolSulfate, Bromhexine Hydrochloride, Cinnarizine, FlunarizineDihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. Brand Electral Completed 50 years in the market and maintains 1st position and touched Rs300 crores. In the biotechnology space, the company is on the verge of breakthrough in third generation Thrombolyte Project to develop the Purification strategy for Reteplase molecule. The Company’s R&D facility is the backbone of its affordable and highly efficient products across categories. It enjoys active operational base in India as well as abroad. Last year, the company completed the buy-back of 29,00,000 equity shares at a price of Rs475 per equity share, comprising of 1.71 per cent of pre-buyback paid up equity share capital of the company. Current year’s heat wave has reportedly vaulted sales of brand leaders Electral and Enerzal to record levels. Trackers expect the company to report a very good Q1. Buy for short term target of Rs390 and medium term target of Rs500.